Stock price when the opinion was issued
Developing drugs for MS and blood cancers like leukemia. Exciting prospects; boasts promising clinical trial results, especially for their MS drug. Last month, they announced good phase 3 results for that drug which lifted share from the $30's to $50's. Cash flow is fine; they just said they've raised a lot of money.